Filed Pursuant to Rule 433
Registration Statement No. 333-259205


 PRELIMINARY KEY TERMS
 

•
CUSIP: 78016FQU1
•
Trade Date: August 26, 2022
•
Settlement Date: August 31, 2022
•
Valuation Date: February 26, 2025
•
Maturity Date: March 3, 2025
•
Term: 2.5 years
•
Reference Asset: the S&P 500® Index (SPX)
•
Buffer Level: 85% of the Initial Level
•
Buffer Percentage: 15%
•
Maximum Return: 137.50%
•
Percentage Change of the Reference Asset:

 INVESTMENT THESIS
 
•
Receive a one-for-one positive return if the level of the Reference Asset increases from the Initial Level to the Final Level, subject to the Maximum Redemption Amount of 137.50% of the principal amount of the notes.
•
Return of principal if the Reference Asset does not decrease by more than 15%.
•
Subject to 1% loss of the principal amount for each 1% that the Reference Asset decreases below the Buffer Level if the Final Level is less than the Buffer Level.

 KEY RISK FACTORS
 

•
The notes are subject to Royal Bank of Canada’s credit risk.
•
The notes are not principal protected.
•
Your notes are likely to have limited liquidity.
•
Your potential payment at maturity Is limited.
•
Please see the following page for important risk factor information.

 TAX
 

•
Each investor will agree to treat the notes as a pre-paid cash-settled derivative contract for U.S. federal income tax purposes, as described in more detail in the product prospectus supplement.
 PAYMENT AT MATURITY GRAPH
 
DETERMINING PAYMENT AT MATURITY
You will lose 1% of the principal amount for each 1% decline in the level of the Reference Asset beyond the Buffer Level. The payment at maturity per $1,000 in principal amount of the notes will be calculated as follows:
$1,000 + [$1,000 x (Percentage Change + Buffer Percentage)]
In this case, you may lose up to 85% of the principal amount at maturity.

Additional Key Information:
This document is a summary of the preliminary terms of an equity linked note that Royal Bank of Canada will issue.  It does not contain all of the material terms of, or risks related to, these notes. You should read the preliminary terms supplement for the notes and the documents described above before investing. In addition, you should consult your accounting, legal and tax advisors before investing.  The preliminary terms supplement for this offering will be provided to you prior to your investment decision, and it may also be accessed here: https://www.sec.gov/Archives/edgar/data/1000275/000114036122027765/brhc10040297_fwp.htm
The notes are not bail-inable notes under the Canada Deposit Insurance Corporation Act.
You should review the preliminary terms supplement carefully prior to investing in the notes.  In particular, you should carefully review the relevant risk factors set forth therein, including, but not limited to, the following:


 •
You May Lose a Substantial Portion of Your Principal Amount, Depending Upon the Performance of the Reference Asset.

•
The Notes Do Not Pay Interest and Your Return May Be Lower than the Return on a Conventional Debt Security of Comparable Maturity.

•
Your Potential Payment at Maturity Is Limited.

•
Payments on the Notes Are Subject to Our Credit Risk, and Changes in Our Credit Ratings Are Expected to Affect the Market Value of the Notes.

•
There May Not Be an Active Trading Market for the Notes—Sales in the Secondary Market May Result in Significant Losses.

•
An Investment in the Notes Is Subject to Risks Relating to Non-U.S. Securities Markets.

•
The Payments on the Notes Will Not Be Adjusted for Changes in Exchange Rates.

•
You Will Not Have Any Rights to the Securities Included in the Reference Asset.

•
The Initial Estimated Value of the Notes Will Be Less than the Price to the Public.

•
The Initial Estimated Value of the Notes that We Will Provide in the Final Pricing Supplement Will Be an Estimate Only, Calculated as of the Time the Terms of the Notes Are Set.

•
Our Business Activities May Create Conflicts of Interest.

•
The Payment at Maturity and the Valuation Date Are Subject to Postponement if a Market Disruption Event Occurs.

The SPX is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates (“SPDJI”), and has been licensed for use by Royal Bank of Canada.  Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”).  The Notes are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates, and none of such parties make any representation regarding the advisability of investing in the Notes nor do they have any liability for any errors, omissions, or interruptions of the SPX.
RBC Capital Markets is the global brand name for the capital markets business of Royal Bank of Canada and its affiliates, including RBC Capital Markets, LLC (member FINRA, NYSE and SIPC); RBC Dominion Securities Inc. (member IIROC and CIPF); Royal Bank of Canada - Sydney Branch (ABN 86 076 940 880); RBC Capital Markets (Hong Kong) Limited (regulated by the Securities and Futures Commission of Hong Kong and the Hong Kong Monetary Authority) and RBC Europe Limited (authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and Prudential Regulation Authority.) ® Registered trademark of Royal Bank of Canada. Used under license. All rights reserved.
Royal Bank of Canada has filed a registration statement (including a product prospectus supplement, a prospectus supplement, and a prospectus) with the SEC for the offering to which this document relates. Before you invest, you should read those documents and the other documents relating to this offering that we have filed with the SEC for more complete information about us and this offering. You may obtain these documents without cost by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Royal Bank of Canada, any agent or any dealer participating in this offering will arrange to send you the product prospectus supplement, the prospectus supplement and the prospectus if you so request by calling toll-free at 1-877-688-2301.